Cantor Fitzgerald analyst Kristen Kluska downgraded Evelo Biosciences to Neutral from Overweight with a price target of $1, down from $5. There were no surprises in the Q4 and FY22 report after the recent February 1 clinical and business updates, and while the firm thinks the small intestinal axis platform has a lot of potential, all the small details are still being worked out towards bringing the most promising candidates forward, the analyst tells investors in a research note. The company is going to require significant capital to bring EDP1815 forward in pivotal trials for psoriasis, and to move the rest of the pipeline forward, Cantor Fitzgerald contends.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EVLO:
- Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
- Evelo Biosciences reports Q4 EPS (21c), consensus (28c)
- Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
- Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
- Evelo Biosciences commences dosing EDP2939 in Phase 2 trial